Chardan Capital Forecasts Strong Price Appreciation for Opus Genetics (NASDAQ:IRD) Stock

Opus Genetics (NASDAQ:IRD) had its price target boosted by Chardan Capital from $9.00 to $11.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target points to a potential upside of 118.69% from the stock’s current price.

IRD has been the subject of a number of other research reports. Lifesci Capital raised shares of Opus Genetics to a “strong-buy” rating in a research report on Thursday, February 12th. B. Riley Financial initiated coverage on shares of Opus Genetics in a research note on Wednesday, December 10th. They set a “buy” rating and a $9.00 price objective on the stock. Piper Sandler assumed coverage on shares of Opus Genetics in a report on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price objective for the company. Brookline Capital Acquisition raised shares of Opus Genetics to a “strong-buy” rating in a research report on Monday, December 1st. Finally, Wedbush upped their target price on shares of Opus Genetics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $9.25.

Opus Genetics Stock Performance

Shares of IRD opened at $5.03 on Thursday. The business’s 50 day moving average is $3.19 and its two-hundred day moving average is $2.32. Opus Genetics has a 52-week low of $0.65 and a 52-week high of $5.30. The firm has a market cap of $346.87 million, a price-to-earnings ratio of -6.13 and a beta of 0.45. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.18.

Insider Buying and Selling at Opus Genetics

In other news, Director Cam Gallagher purchased 83,000 shares of the stock in a transaction dated Monday, December 29th. The stock was acquired at an average cost of $1.97 per share, for a total transaction of $163,510.00. Following the acquisition, the director owned 83,000 shares of the company’s stock, valued at $163,510. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On Opus Genetics

A number of hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in Opus Genetics during the fourth quarter valued at $34,000. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics in the 4th quarter worth about $25,000. Opaleye Management Inc. lifted its position in shares of Opus Genetics by 1.8% in the 4th quarter. Opaleye Management Inc. now owns 1,120,000 shares of the company’s stock worth $2,251,000 after buying an additional 20,000 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Opus Genetics in the 4th quarter valued at about $4,025,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Opus Genetics during the fourth quarter valued at approximately $5,463,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Key Headlines Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple firms raised price targets and reiterated positive ratings (supports upside momentum). Chardan raised its target to $11 with a Buy rating. Chardan price target raise
• Positive Sentiment: Wedbush boosted its target to $10 and kept an Outperform rating—another endorsement from a sell‑side shop. Wedbush price target raise
• Positive Sentiment: BTIG raised its price target to $12 (from $7) and maintained a Buy—adds to the cluster of higher targets that can drive investor interest. BTIG note
• Positive Sentiment: Clinical update: Opus provided progress on its Nyxol (oxymetazoline) clinical program (Phase 3 presbyopia/night‑vision studies), which is a near‑term catalyst investors watch for regulatory/market readthroughs. Clinical trial update
• Neutral Sentiment: H.C. Wainwright publicly remains constructive on Opus (keeps a Buy stance), which supports ongoing investor confidence even amid forecast changes. HC Wainwright buy rating
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across 2026 quarters and lowered FY2026 (to −$0.64) and FY2027/FY2028 forecasts substantially — this reflects a darker near‑term profitability outlook and could pressure the stock if clinical/operational progress stalls.
• Negative Sentiment: Lifesci Capital also trimmed Q1/Q2 and FY2026 EPS estimates (despite keeping a Strong‑Buy rating), signaling some analyst caution about timing or magnitude of revenue/cost assumptions.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.